"A veteran of the international biotech industry, Mr. Liang Qibin has an extensive global executive career spanning almost 30 years in the operation and management CMC of biologics in China and abroad."
A veteran of the international biotech industry, Mr. Liang Qibin has an extensive global executive career spanning almost 30 years in the operation and management CMC of biologics in China and abroad.
In his early roles he worked for leading US-based biopharmaceutical companies including Bayer, Genentech, and Progenics where he managed upstream and downstream departments to produce a range of late-stage and commercial biologic products. His unique background combines proven experience in both CMC/GMP and team management.
He subsequently facilitated the construction of 6 cGMP facilities, involving the commercialization of 3 first-in-class biological drugs, and the technical development/scale-up of one ADC (antibody drug conjugation) new drug.
Since 2011 Mr. Liang has been working in China where he has been instrumental in setting up four biologics development and GMP manufacturing facilities, and one of them has successfully past the US FDA PAI. Before joining CMAB, he was the President of MabPlex International, Yantai, China.
Mr. Liang holds a Master of Science (Chemical Engineering) degree from University of Idaho and a Bachelor of Science (Chemical Engineering) from East China University of Technology.
"With more than two decades of international experience in the pharmaceutical and biotech industry, Michael Frizberg is responsible for CMAB's global strategy and business development."
With more than two decades of international experience in the pharmaceutical and biotech industry, Michael Frizberg is responsible for CMAB's global strategy and business development.
Michael's career started in Hong Kong in 1995, followed by various senior positions at Sanofi-Aventis including Global Supply Chain and Global Market Research responsibilities before joining Lonza.
At Lonza Michael led several key global functions including Marketing, Corporate Communications, Investor Relations, Business Development and Sales. His initiative to create a biosmilar-driven business unit through a joint venture with one of the leading pharmaceutical companies in the world was, at the time, a major strategic move for Lonza and the industry. He also served for several years as the Chairman to the Board of a Swiss-Chinese pharmaceutical venture, which he established in 2012.
Immediately before joining CMAB, Michael was General Manager of the European division of Luye Pharma.
Michael holds a Master of Arts in Economics from Wayne State University (USA) as well as a Diplom Kaufmann (MBA) from University of Augsburg (Germany).